Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R8LN
|
|||
| Former ID |
DNC009920
|
|||
| Drug Name |
N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide
|
|||
| Synonyms |
CHEMBL572484; N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H19NO3
|
|||
| Canonical SMILES |
COC1=CC=CC(=C1)CCC2=CC=C(C=C2)N3C(=O)C4=CC=CC=C4C3=O
|
|||
| InChI |
1S/C23H19NO3/c1-27-19-6-4-5-17(15-19)10-9-16-11-13-18(14-12-16)24-22(25)20-7-2-3-8-21(20)23(24)26/h2-8,11-15H,9-10H2,1H3
|
|||
| InChIKey |
CNZNMDJWLSHLJZ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxysterols receptor LXR-alpha (NR1H3) | Target Info | Inhibitor | [1] |
| Oxysterols receptor LXR-beta (NR1H2) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | PPAR signaling pathway | |||
| Non-alcoholic fatty liver disease (NAFLD) | ||||
| Hepatitis C | ||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | SREBP signalling | |||
| Nuclear Receptors | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | ||||
| PPAR Alpha Pathway | ||||
| Liver X Receptor Pathway | ||||
| Adipogenesis | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.